Overcoming Obesity 2023 (Live) -Efficacy and Safety of Intermittent Fasting in Patients with Metabolic Syndrome, Pre-Diabetes and T2DM
Intermittent Fasting (IF) as a means of dietary modification has gained popularity among individuals with obesity as a means of achieving weight loss. Especially within recent years, the utility of IF has grown in patients with metabolic syndrome, pre-diabetes and type 2 diabetes mellitus (T2DM).
The focus of this presentation will be the utility of IF regimens as a means of weight loss in patients with T2DM using hypoglycemic agents. Dr. Rajpal will discuss and suggest preventive measures to minimize the adverse effects of IF regimens in this special population.
CME/CE Expiration Date: 11/28/23
*The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.
Aman Rajpal, MD, DABOM
- 0.75 AMA PRA Category 1 Credit™The Obesity Medicine Association (OMA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Obesity Medicine Association designates this Live activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the commensurate amount with the extent of their participation in the activity.